JP2527132C - - Google Patents
Info
- Publication number
- JP2527132C JP2527132C JP2527132C JP 2527132 C JP2527132 C JP 2527132C JP 2527132 C JP2527132 C JP 2527132C
- Authority
- JP
- Japan
- Prior art keywords
- affected area
- coating layer
- bleeding
- affected
- hydrophilic polysaccharide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 claims description 15
- 150000004676 glycans Chemical class 0.000 claims description 14
- 229920001282 polysaccharide Polymers 0.000 claims description 14
- 239000005017 polysaccharide Substances 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 12
- 239000000843 powder Substances 0.000 claims description 10
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical group O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 claims description 7
- 229920002581 Glucomannan Polymers 0.000 claims description 7
- 229920002907 Guar gum Polymers 0.000 claims description 7
- 229940046240 glucomannan Drugs 0.000 claims description 7
- 229960002154 guar gum Drugs 0.000 claims description 7
- 235000010417 guar gum Nutrition 0.000 claims description 7
- 239000000665 guar gum Substances 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 7
- 206010052428 Wound Diseases 0.000 description 13
- 208000027418 Wounds and injury Diseases 0.000 description 13
- 239000011247 coating layer Substances 0.000 description 11
- 230000000740 bleeding effect Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 210000000416 exudates and transudate Anatomy 0.000 description 9
- 230000035876 healing Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 208000033809 Suppuration Diseases 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000023597 hemostasis Effects 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 208000003322 Coinfection Diseases 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 206010039509 Scab Diseases 0.000 description 2
- 229960001950 benzethonium chloride Drugs 0.000 description 2
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 2
- IVHBBMHQKZBJEU-UHFFFAOYSA-N cinchocaine hydrochloride Chemical compound [Cl-].C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCC[NH+](CC)CC)=C21 IVHBBMHQKZBJEU-UHFFFAOYSA-N 0.000 description 2
- 229940045574 dibucaine hydrochloride Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000019300 CLIPPERS Diseases 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 208000021930 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids Diseases 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2527132B2 (ja) | 親水性多糖類よりなる外用薬組成物 | |
Thomas | Alginate dressings in surgery and wound management: Part 2 | |
EP0162026B1 (en) | A bacteria adsorbing composition | |
EP2755676B1 (en) | Composition and dressing for wound treatment | |
KR101320960B1 (ko) | 키토산-글루칸을 포함하는, 상처 치유 및 상처에의 붕대 유착 방지용 제제 | |
RU2707254C1 (ru) | Водный фармацевтический препарат и способ лечения хронической язвы | |
EP2340053B1 (en) | Wound care device | |
JPH04502569A (ja) | 創傷治療用ゲル配合物 | |
CA2095077C (en) | Freeze-dried pad | |
O'Shaughnessy et al. | Calcium alginate dressings promote healing of split skin graft donor sites | |
Ajiteru et al. | Fabrication and characterization of a myrrh hydrocolloid dressing for dermal wound healing | |
JP2004530448A (ja) | 局所適用される凝血材料 | |
US8252335B2 (en) | Healing powder and method of use thereof | |
Jacobsen | Update on wound dressings: indications and best use | |
TW201737938A (zh) | 慢性傷口之清創方法 | |
HU201683B (en) | Process for producing pharmaceutical compositions for promoting healing of wounds | |
Van Gils et al. | Improved healing with a collagen-alginate dressing in the chemical matricectomy | |
JP2527132C (enrdf_load_stackoverflow) | ||
Ghanim et al. | Insight into Topical Preparations for Wound Healing: Traditional and Modern Dressings. | |
RU2331444C1 (ru) | Повязка для лечения ран | |
RU12971U1 (ru) | Губка | |
Ljungberg et al. | Dextranomer for treatment of venous leg ulcers: paste versus bead formulation | |
Firlar et al. | eScholarship@ UMassChan | |
Kumarasinghe | Wound Care Management and Dressing Materials | |
Ajiteru et al. | Colloid and Interface Science Communications |